Anti-Ai new drug Rui Aito on the market in China

on April 20,, Baxter announced that its self-developed world's first daily daily administration of protease inhibitor sourase inhibitor Siato (Azanavir) has been approved for listing in China by the State FoodDrugAdministrationReaita is a new protease inhibitor, with sustained and powerful suppression of HIV virus, low drug resistance, convenient drug use, small side effects on fat metabolism and so onProtease is a necessary substance for HIV virus replication, and protease inhibitors can effectively block the synthesis of HIV proteaseAs a powerful protease inhibitor, Reato is used in antiviral therapy with other antiviral drugs, and only 2% of patients who have never received antiviral treatment are resistantBy the end of 2006, about 130,000 patients in the United States alone had received treatment for Reato" In the initial treatment of aids patients with antiviral, the efficacy of the program containing Reato is equivalent to the currentstandardtreatment plan, but Reato because of the daily administration of 1 time, small side effects of fat metabolism, low resistance rate, and other protease inhibitors without cross-resistance and so on, to make it more advantageous"DrZhang Fujie, director of the Center for Diseaseprevention and control of china'sdiseases and prevention center, and lead researcher in clinical trials in China, said: "In patients treated with antivirals, Reato needs to be used in combination with Litonevir, which is comparable to the currentstandardtreatment options, while Reaito has the smallest side effects of fat metabolism in existing protease inhibitors." "Because increased side effects on fat metabolism can cause increased blood lipids in patients, it may increase the risk of cardiovascular disease According to Dr Zhang Fujie, in China, about 5,000 to 10,000 new HIV/AIDS patients who have never been treated each year, the number of free government patients has exceeded 36,000, and the rate of about 6,000 per year is increasing, of which about 20% of patients are resistant to the first-line treatment program, and need second-line treatment drugs " Pertsa-Squibb is one of the world's top three anti-AIDS drug research and development and manufacturers Following the listing of anti-ae-esitt (Steinftin) and Whittox (dehydrocarbonmynside) in China, it is today listed as a representative of the latest medical achievements worldwide "Hopefully this innovative drug will provide better treatment options for more Chinese AIDS patients, " said Mr Ko, President of 100-Times Meishi Squibao (China) "
(reproduced from the Journal of Medicine and Economics)